Quick Answer
Oncotelic Therapeutics, Inc. reported Total Revenue of $70.0 thousand for fiscal year 2023.
Oncotelic Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2023 | $70.0K | -96.0% |
| 2020 | $1.74M | +1732.5% |
| 2013 | $95.0K | -39.1% |
| 2012 | $156.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $70.0K | — | -95.0% |
| June 30, 2020 | $1.40M | — | +310.7% |
| March 31, 2020 | $340.9K | — | +258.8% |
| September 30, 2013 | $95.0K | — | -16.7% |
| March 31, 2012 | $114.0K | — | — |
- Oncotelic Therapeutics, Inc. showed a decrease of -96.0% in Total Revenue compared to the prior fiscal year.
- Over the 2012–2023 period, Oncotelic Therapeutics, Inc.’s total revenue has declined by 55.1% (from $156.0 thousand to $70.0 thousand).
- The most recent figure is from Oncotelic Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: